Research site

Multiprofile Hospital For Active Treatment Knyaginya Klementina Sofia EAD

Bulgaria Bulevard Gen. Stoletov No 67a, 1233 Sofia, Bulgaria

20 trials recruiting
Chronic obstructive pulmonary disease · Asthma · Atrial fibrillation
Adults and children

About Specializations

Multiprofile Hospital For Active Treatment Knyaginya Klementina Sofia EAD in Sofia, Bulgaria specialises in clinical trials of conditions such as Chronic obstructive pulmonary disease, Asthma, Atrial fibrillation, Type 2 diabetes mellitus, and other specialisations. This site conducts important research.

Main research areas of the site

Respiratory Medicine

The medical center is at the forefront of respiratory medicine, focusing on innovative treatments for Chronic Obstructive Pulmonary Disease (COPD). The center's research is dedicated to improving patient outcomes through advanced therapeutic strategies.

Chronic Obstructive Pulmonary Disease (COPD)
Astegolimab Efficacy and Safety
Reduction of COPD Exacerbations

By conducting pivotal studies, the center contributes significantly to the understanding and management of COPD, aiming to reduce the frequency and severity of exacerbations and enhance the quality of life for patients.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Bulevard Gen. Stoletov No 67a1233 SofiaBulgaria

Open in maps ↗

Recruiting now: 20 trials
Conditions studied: 20

More sites in Sofia Bulgaria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

44 clinical trials

Chronic obstructive pulmonary disease

Recruiting

Investigational

Study of PF-07275315 versus placebo for efficacy and safety in adults with moderate-to-severe chronic obstructive pulmonary disease (COPD)

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Sponsor:Pfizer Inc.

Contact Research Centre

Type 2 diabetes mellitus+2

Recruiting

Registered drug

Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:Semaglutide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Chronic obstructive pulmonary disease

Recruiting

Registered drug

A study to evaluate the efficacy and safety of depemokimab and salbutamol sulfate in patients with chronic obstructive pulmonary disease and type 2 inflammation.

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:Depemokimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Cardiac failure

Recruiting

Investigational

Study of PF-07328948 tablets compared to placebo in adults with heart failure to evaluate effects on symptoms and physical function

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Sponsor:Pfizer Inc.

Contact Research Centre

Acute respiratory failure

Recruiting

Investigational

Study on Tozorakimab for Patients Hospitalized with Severe Viral Lung Infections Needing Oxygen

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:Tozorakimab
Sponsor:AstraZeneca AB

Contact Research Centre

Chronic obstructive pulmonary disease

Recruiting

Registered drugNo placebo

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo

Bulgaria

Participants:18–64 years · 65+ years
Substances:Budesonide
Sponsor:AstraZeneca AB

Contact Research Centre

Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

Recruiting

Investigational

Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:Finerenone
Sponsor:Colorado Prevention Center

Contact Research Centre

Atrial fibrillation

Recruiting

Investigational

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational

Bulgaria

Participants:65+ years
Substances:Abelacimab
Sponsor:Anthos Therapeutics Inc.

Contact Research Centre

Atrial fibrillation

Recruiting

Investigational

Efficacy and Safety of BAY 3670549 in Adults with Atrial Fibrillation: A Randomized, Double‑Blind, Placebo‑Controlled Phase 2 Study

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Sponsor:Bayer AG

Contact Research Centre

Asthma

Recruiting

Registered drug

Efficacy and Safety of Depemokimab for Early Intervention in Adults and Adolescents with Type 2 Asthma at Risk of Exacerbations

Registered drug

Bulgaria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Depemokimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Asthma

Recruiting

Investigational

GB-0895 for Severe Uncontrolled Asthma in Adults and Adolescents

Investigational

Bulgaria

Participants:0–17 years · 18–64 years · 65+ years
Sponsor:Generate Biomedicines Inc.

Contact Research Centre

Graves' disease

Recruiting

InvestigationalNo placebo

Long-Term Study of Imeroprubart in Adults With Graves' Disease

InvestigationalNo placebo

Bulgaria

Participants:18–64 years · 65+ years
Substances:IMEROPRUBART
Sponsor:Immunovant Sciences GmbH

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites